Kymera Therapeutics (NASDAQ:KYMR) executives highlighted a sharpened strategic focus on immunology and inflammation at Oppenheimer’s 36th Annual Healthcare Conference, emphasizing progress in its STAT6 degrader KT-621, the start of clinical dosing for its IRF5 program, and a financial position the company said provides runway into 2029. Strategy shift toward IMiD degraders and current scale Management […]